Navigation Links
New Treatment Aids Weight Loss, Improves Diabetes in Monkeys
Date:11/28/2012

By Serena Gordon
HealthDay Reporter

WEDNESDAY, Nov. 28 (HealthDay News) -- A new, lab-created antibody that mimics the action of a naturally occurring molecule causes weight loss in monkeys, researchers report.

The engineered antibody also appears to improve insulin sensitivity, which could fight type 2 diabetes, and it decreases levels of triglycerides, a blood fat that contributes to hardening of the arteries.

"The results we describe in animal models are profound and very encouraging," said study senior author Yang Li, scientific director at Amgen, Inc., in Thousand Oaks, Calif. "While we're excited about these findings, we're still evaluating the results."

Li said it's important to remember these findings were in monkeys and only in a preclinical setting. It's not yet clear how this treatment might act in humans.

The study was funded by Amgen, the developer of the new treatment. The findings are published in the Nov. 28 issue of Science Translational Medicine.

Obesity and its frequent companion, type 2 diabetes, are growing problems in the United States that threaten to overwhelm the health care system if they continue to increase, according to the U.S. Centers for Disease Control and Prevention. Obesity treatments generally aren't effective in the long term, and while medications are available for type 2 diabetes, many people with the disease aren't able to achieve blood sugar levels low enough to avoid complications, according to the American Diabetes Association.

The current study began by looking at a molecule called fibroblast growth factor 21 (FGF21). This molecule has garnered a lot of research interest lately because it appears to have many positive effects on obesity and type 2 diabetes, according to the study.

In the body, FGF21 is induced during fasting or starvation. Scientists are still trying to understand how FGF21 causes beneficial changes, but suspect it may activate the less common but more metabolically active brown fat.

Developing FGF21 into a treatment is challenging, Li said, because the molecule isn't stable in the blood. That means any treatment developed from the natural protein might require frequent injections, he said.

In the current research, Li and his colleagues took a different approach. Instead of looking at FGF21, the researchers attempted to find other, more stable ways to activate the same pathways activated by FGF21.

The researchers engineered an alternative in the lab -- an antibody called mimAb1. They tested the new antibody on 10 obese monkeys and compared them to another 10 obese monkeys in a control group.

The monkeys in the treatment group received two injections -- one the first week and another the third week. Five to six weeks after the first injection the monkeys had lost 10 percent of their body weight. The reductions in body weight were maintained at least nine weeks after the second injection.

What's more, the weight loss appeared to occur even without a significant reduction in calories, Li said.

In addition to weight loss and improved insulin sensitivity, the animals' abdominal circumference and body-mass index (BMI) decreased. BMI is a measure of body fat based on height and weight.

"When we tested mimAb1 in the animal model, we saw a lot of beneficial changes. The results were quite encouraging," Li said. He added that they didn't see any significant side effects, including low blood sugar levels.

Dr. Spyros Mezitis, an endocrinologist at Lenox Hill Hospital in New York City, said the study was well done, but it's very preliminary.

"There is promise here. This pathway has beneficial effects when turned on, and needs to be looked into further," Mezitis said. "We have to make sure it works the same way in humans, and that it's safe. This might take years to pan out."

He said it's also possible that although this particular treatment may not be the answer for human obesity or diabetes, it may provide more clues into the mechanisms behind these conditions.

More information

Read more about current ways to maintain a healthy weight from the U.S. National Heart, Lung, and Blood Institute.

SOURCES: Yang Li, Ph.D., scientific director, Amgen, Inc., Thousand Oaks, Calif.; Spyros Mezitis, M.D., endocrinologist, Lenox Hill Hospital, New York City; Nov. 28, 2012, Science Translational Medicine


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New hope for setback-dogged cancer treatment
2. The hidden disorder: Unique treatment proposed for childrens neurological disorder
3. Drug resistance biomarker could improve cancer treatment
4. Pathway identified in human lymphoma points way to new blood cancer treatments
5. Scientists win funding to study new treatment for severe chronic pain
6. Researchers find decline in availability and use of key treatment for depression
7. New technology for a more efficient treatment of Pompe disease and other metabolic disorders
8. Hepatitis C treatments side effects can now be studied in the lab
9. Researchers report potential new treatment to stop Alzheimers disease
10. Study shows bone metastases treatment can improve overall survival
11. GW researcher receives $4.1 million grant to find alternative treatment for kidney stones
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Treatment Aids Weight Loss, Improves Diabetes in Monkeys
(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased ... a convenient service for Texas, they are expanding their presence in Dallas. One of ... spree that will bring new jobs to the Dallas and Forth Worth market. STAT ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged to ... mind, SIGVARIS has created a new line of anti-embolism stockings to help prevent ... the benefits of graduated compression when transitioning from recovery to early rehabilitation. , ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... AMSTERDAM , December 8, 2016 Information ... TM metrics in Scopus , the world,s largest ... free access to comprehensive metrics for journals from over 5,000 publishers. ... publish, which journals to subscribe to and when to adjust a ... , , ...
(Date:12/8/2016)... 2016 According to the research report, ... is expected to be worth US$9.7 bn by the ... Between the forecast years of 2016 and 2024, the global ... The leading players operating in the global diabetes injection pens ... plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports ...
(Date:12/8/2016)... 2016 According to a new market research report ... Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart watch, Patch), ... global market, in terms of value, is projected to reach 12.14 Billion ... 18.0% during the forecast period. Continue Reading ... ...
Breaking Medicine Technology: